1. Home
  2. SLVM vs TRAX Comparison

SLVM vs TRAX Comparison

Compare SLVM & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

SELL

Current Price

$32.28

Market Cap

1.3B

ML Signal

SELL

TRAX

First Tracks Biotherapeutics Inc. Ordinary Shares

SELL

Current Price

$35.09

Market Cap

1.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SLVM
TRAX
Founded
1898
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
SLVM
TRAX
Price
$32.28
$35.09
Analyst Decision
Buy
Strong Buy
Analyst Count
4
12
Target Price
$48.00
★ $72.50
AVG Volume (30 Days)
336.7K
★ 1.0M
Earning Date
11-06-2026
11-12-2026
Dividend Yield
★ 5.61%
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $3,351,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.67
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$30.40
$15.69
52 Week High
$56.80
$49.91

Technical Indicators

Market Signals
Indicator
SLVM
TRAX
Relative Strength Index (RSI) 40.74 48.71
Support Level N/A $30.11
Resistance Level $40.13 $48.94
Average True Range (ATR) 1.33 2.84
MACD -0.07 0.26
Stochastic Oscillator 35.25 46.87

Price Performance

Historical Comparison
SLVM
TRAX

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

About TRAX First Tracks Biotherapeutics Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

Share on Social Networks: